Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment

Background Systemic hypertension (SH) is common in dogs and humans with hypercortisolism and can persist after treatment. Objectives To evaluate changes in prevalence of SH and systolic blood pressure (SBP) in dogs with pituitary‐dependent hyperadrenocorticism (PDH) during the first year of trilosta...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary internal medicine 2021-01, Vol.35 (1), p.130-141
Main Authors: García San José, Paula, Arenas Bermejo, Carolina, Alonso‐Miguel, Daniel, Clares Moral, Irene, Cuesta‐Alvaro, Pedro, Pérez Alenza, María Dolores
Format: Article
Language:English
Subjects:
angiotensin converting enzyme inhibitors
Antihypertensives
benazepril
Blood pressure
canine
cortisol
Cushing's
Drug dosages
Enzymes
GLP-1 receptor agonists
Hormones
Hypertension
Potassium
SMALL ANIMAL
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Systemic hypertension (SH) is common in dogs and humans with hypercortisolism and can persist after treatment. Objectives To evaluate changes in prevalence of SH and systolic blood pressure (SBP) in dogs with pituitary‐dependent hyperadrenocorticism (PDH) during the first year of trilostane treatment, its relationship with disease control and selected laboratory variables, and their response to antihypertensive treatment. Animals Fifty‐one dogs with PDH treated with trilostane Q12h. Methods Prospective case series study. Dogs were evaluated at diagnosis (T0) and 1, 3, 6, and 12 months (T12). Dogs were classified as nonhypertensive (SBP 
ISSN:0891-6640
1939-1676
DOI:10.1111/jvim.15978